Abstract |
The development of proteomic methods, especially mass spectrometry, has brought new possibilities to tumor marker research. Pancreatic secretory trypsin inhibitor (PSTI), a common known biomarker for various malignancies, occurs on genetic variants that we are able to detect at the protein level with proteomic techniques using immunoaffinity capture prior to liquid chromatography-mass spectrometry (LC-MS). We also show that PSTI can be detected in urine from cancer patients using a two-step peptide enrichment technique and LC-MS. These results show that tumor-associated peptides can be detected in urine by proteomic techniques.
|
Authors | Leena Valmu, Suvi Ravela, Ulf-Håkan Stenman |
Journal | Methods in molecular biology (Clifton, N.J.)
(Methods Mol Biol)
Vol. 641
Pg. 347-57
( 2010)
ISSN: 1940-6029 [Electronic] United States |
PMID | 20407956
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carrier Proteins
- Peptides
- SPINK1 protein, human
- Trypsin Inhibitors
- Trypsin Inhibitor, Kazal Pancreatic
|
Topics |
- Analytic Sample Preparation Methods
- Carrier Proteins
(immunology, urine)
- Chromatography, Liquid
- Humans
- Male
- Pancreatitis
(urine)
- Peptides
(urine)
- Prostatic Neoplasms
(urine)
- Proteomics
(methods)
- Spectrometry, Mass, Electrospray Ionization
- Trypsin Inhibitor, Kazal Pancreatic
- Trypsin Inhibitors
(immunology, urine)
- Urinalysis
(methods)
|